Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (12366)	12/2/1999 12:08:00 AM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Check Abgenix news, it seems that their mice are working full time now. 8 major agreements including powers like Chiron, Human Genome Project, and their own Psoriasis phase II report. Abgenix like PDLI do not have much more pipeline than xoma, but different and like PDLI they can command respect in the market, well they do not have two major pIII failures either. So xoma must be undervalued (if meningo good of course, but looking at the former two it seems like even without meningo xoma is quite similar to them but market value). Bluegreen was clear is not xoma, is the xomies investing on it. Nice finding about some eye problems/solutions for year 2001. xoma supposedly got $11 millions for this and it seems that Allergan either did not force the money for this particular development then xoma got great deal then where is the money? another waste of money and time? Waste is a terrible thing to mind.